YJ1206

Biorbyt

YJ1206

10

Research Use Only

YJ1206 is a selective CDK12/CDK13 PROTAC degrader with oral activity, demonstrating an IC50 of 12.55 nM in VCaP cells. It enhances DNA damage, induces apoptosis, and promotes tumor regression in a castration-resistant prostate cancer PDX (patient-derived xenograft) mouse model derived from original site WA74. Additionally, YJ1206 acts synergistically with AKT pathway inhibitors to suppress in vivo tumor growth.

-20°C

12352200